Event
MJFF 2025 Parkinson’s Disease Therapeutics
📅 Date: October 16, 2025
📍 Location: New York, NY, USA
Tom Grammatopoulos,
BD Senior Director North America
Advancing discovery at MJFF 2025 Parkinson’s Disease Therapeutics
Axxam will attend MJFF 2025 Parkinson’s Disease Therapeutics in New York. The meeting, organized by the Michael J. Fox Foundation, convenes leading scientists, biotechs, pharma teams, and investors to accelerate progress in Parkinson’s disease. Our Senior Director, BD North America, Tom, will participate in the Main Conference on October 16. Therefore, this event offers a focused setting to discuss programs, explore collaboration paths, and identify the next practical steps.
From biology to impact: neuro-focused capabilities for PD programs
For over two decades, Axxam has supported early discovery with assay development, HTS/HCS platforms, iPSC-based neuronal models, GPCR and ion channel assays, and mechanistic profiling. Moreover, our electrophysiology capabilities—including automated patch-clamp and organelle-level readouts—deliver precise functional insights. Consequently, partners can de-risk decisions earlier while maintaining scientific rigor. In addition, ISO-certified processes and transparent reporting ensure reproducibility, which, in turn, streamlines transitions between screening, validation, and hit-to-lead.
Why meet Axxam at MJFF 2025 Parkinson’s Disease Therapeutics
Programs in Parkinson’s disease demand depth in biology and speed in execution. Thus, we tailor workflows for target validation, phenotypic screening, and mechanism-of-action studies. Furthermore, our flexible collaboration models adapt to biotech and pharma priorities, whether you need a full campaign or modular support. As a result, your team gains data you can trust—and a partner that helps move from signal to strategy.
📍 Let’s connect in New Yoek
If you are attending MJFF 2025 Parkinson’s Disease Therapeutics, let’s talk. Contact us to schedule time with Tom, align on your objectives, and map an efficient plan for your PD portfolio. Together, we can translate promising ideas into actionable outcomes.